Meta-analysis of the diagnostic performance of circulating microRNAs for pancreatic cancer

Cheng Peng

Central South University Third Xiangya Hospital

Zhiqiang Li

Central South University Third Xiangya Hospital

Lihua Huang

Central South University Third Xiangya Hospital

Wenzhe Gao

Central South University Third Xiangya Hospital

Jiale Wang

Central South University Third Xiangya Hospital

Yunfei Liu

Central South University Third Xiangya Hospital

Xia Li

Central South University Third Xiangya Hospital

Xiao Yu (✉ yuxiaoyx4@126.com)

Central South University Third Xiangya Hospital <https://orcid.org/0000-0002-3172-8606>

Research article

Keywords: pancreatic cancer; microRNAs; diagnosis; meta-analysis; circulating

Posted Date: April 17th, 2020

DOI: <https://doi.org/10.21203/rs.2.18339/v3>

License: This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at International Journal of Medical Sciences on January 1st, 2021. See the published version at <https://doi.org/10.7150/ijms.52706>.

Abstract

Background: Pancreatic cancer (PC) is characterized by high malignancy and a poor prognosis. The detection of circulating microRNAs (miRNAs) is a liquid biopsy diagnostic approaches. Numerous studies have suggested that some differentially expressed miRNAs may be promising diagnostic markers for PC, but the results have varied among studies. The present study was performed to summarize the diagnostic accuracy of circulating miRNAs, carbohydrate antigen 19-9 (CA19-9), and the combination of miRNAs and CA19-9.

Methods: A literature search of online databases including PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI) and WanFang was conducted. Relative data were extracted from eligible included studies, and a meta-analysis was performed.

Results: A total of 46 studies involving 4,326 PC patients and 4,277 non-PC controls were included. The pooled sensitivity (SEN), specificity (SPE) and AUC of the circulating miRNAs for differentiating PC patients from non-PC controls were 0.79 (0.77-0.81), 0.77 (0.75-0.79), and 0.85 (0.81-0.87), respectively. For CA19-9, the SEN, SPE and AUC were 0.78 (0.75-0.80), 0.90 (0.85-0.94) and 0.85 (0.82-0.88), respectively. The combination of miRNAs and CA19-9 greatly improved the SEN, SPE and AUC to 0.84 (0.80-0.87), 0.91 (0.89-0.93) and 0.94 (0.92-0.96), respectively. Moreover, circulating miRNAs also yielded an acceptable diagnostic accuracy for early-stage PC with a SEN of 0.79 (0.76-0.82), a SPE of 0.74 (0.68-0.79) and an AUC of 0.81 (0.77-0.84).

Conclusions: Circulating miRNAs exhibited satisfactory diagnostic performance for PC and even early-stage PC. The combination of circulating miRNAs and the traditional marker CA19-9 can further improve the diagnostic accuracy, providing a novel strategy for PC diagnosis.

1. Background

Pancreatic cancer (PC) is a highly malignant digestive tract cancer characterized by strong invasiveness, a high recurrence rate and a poor prognosis. In 2018, there were approximately 458,918 new cases of PC worldwide, accounting for 2.5% of all new cases of cancer. Meanwhile, 432,242 patients died of PC, making it the seventh most common cause of cancer-related death[1].

According to the recommendation of the US Preventive Services Task Force (USPSTF), screening for PC in asymptomatic individuals is currently not recommended[2]. However, early detection is valuable for individuals with risk factors (such as a familial history) for PC, as it can increase the resection rates and result in longer median survival[3]. Overall, the 5-year survival rate for PC is 9.3%, but it is largely determined by the stage at which PC is diagnosed. For PC patients with metastatic disease at the time of diagnosis, the 5-year survival rate is 2.9%. If regional disease is present, the 5-year survival rate is 12.4%. For patients with localized PC, the 5-year survival rate can increase to 37.4%[4].

Conventional imaging methods, such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US), and serum marker carbohydrate antigen 19-9 (CA19-9) have been widely used for the diagnosis of PC, but the diagnostic accuracy of these modalities may be suboptimal[5], especially for early-stage PC [6]. Endoscopic ultrasonography (EUS) has gradually come to be considered to be the most accurate diagnostic tool since it not only has higher sensitivity (SEN) and specificity (SPE) but can also facilitate the retrieval of specimens of suspected tissue by EUS-guided fine-needle aspiration (EUS-FNA) for pathological confirmation. However, its invasiveness and the risks attendant on sedation make it only suitable for selected individuals[7, 8]. In this clinical setting, liquid biopsy is of great interest from both scientific and clinical perspectives because of its non-invasiveness, higher sensitivity and cost-efficiency[9]. Numerous biomarkers derived from PC, including circulating tumour cells (CTCs), cell-free circulating tumour DNAs (cfDNAs), circulating microRNAs (miRNAs), long non-coding RNAs (lncRNAs), proteins and metabolites, circulating tumour extracellular vesicles (e.g., exosomes) and tumour-educated platelets (TEPs), can be detected by liquid biopsy[6, 9].

MiRNAs are a class of non-coding RNAs 19-25 nucleotides in length that regulate protein synthesis at the post-transcriptional level and play an indispensable role in cancer initiation, proliferation, progression, metastasis and chemo-resistance[10]. Since 2010, many studies on the application of circulating miRNAs for the diagnosis of PC have been published. The purpose of the present study is to summarize these original studies and evaluate the diagnostic performance of circulating miRNAs for PC.

2. Methods

2.1. Literature search and study selection

The process of the literature search and study selection was performed in accordance with the PRISMA guidelines[11]. A combination of MeSH terms and entry terms was used to search the mainstream databases, including PubMed, EMBASE and Cochrane Library. We also searched Chinese databases, including the China National Knowledge Infrastructure (CNKI) and WanFang databases. In addition, we conducted a manual search for potentially eligible studies based on the identified review articles' reference lists. The last retrieval date was August 20, 2019. The search terms we used included (1) circulating, circulatory, serum, plasma, blood; (2) microRNAs, miRNAs, miR, panel; (3) Pancreatic Neoplasms, Pancreatic Intraductal Neoplasms, pancreatic cancer, cancer of pancreas, pancreatic cancer, carcinoma, pancreas, pancreatic ductal adenocarcinoma or PDAC; and (4) screen, diagnosis, diagnostic, prediction, predict, monitor, detection, detect, predictor, marker, sensitivity, specificity, AUC. For example, our electronic search strategy for PubMed was (((((((circulating[Title/Abstract]) OR circulatory[Title/Abstract]) OR serum[Title/Abstract]) OR plasma[Title/Abstract]) OR blood[Title/Abstract]))) AND (((((((Pancreatic Neoplasms[MeSH Terms]) OR Carcinoma, Pancreatic Ductal[MeSH Terms]) OR Pancreatic Intraductal Neoplasms[MeSH Terms]) OR Pancreatic Neoplasms[Title/Abstract]) OR Carcinoma, Pancreatic Ductal[Title/Abstract]) OR Pancreatic Intraductal Neoplasms[Title/Abstract]) OR pancreatic cancer[Title/Abstract]) OR cancer of pancreas[Title/Abstract]) OR pancreatic carcinoma[Title/Abstract]) OR carcinoma of pancreas[Title/Abstract]) OR pancreatic ductal adenocarcinoma[Title/Abstract]) OR PDAC[Title/Abstract])) AND (((((((microRNA[Title/Abstract]) OR microRNAs[Title/Abstract]) OR miRNA[Title/Abstract]) OR miRNAs[Title/Abstract]) OR miR[Title/Abstract]) OR panel[Title/Abstract])) AND (((((((diagnostic[Title/Abstract]) OR diagnosis[Title/Abstract]) OR screen[Title/Abstract]) OR monitor[Title/Abstract]) OR detect[Title/Abstract]) OR predict[Title/Abstract]) OR predictor[Title/Abstract]) OR prediction[Title/Abstract]) OR specificity[Title/Abstract]) OR sensitivity[Title/Abstract]) OR marker[Title/Abstract]) OR AUC[Title/Abstract]) OR detection[Title/Abstract]).

We obtained a substantial number of retrieved records through the database search and manual search. First, duplicated publications were removed by Endnote X9 software, and then we checked again to ensure that there were no duplicate records. The remaining articles were evaluated based on their titles and abstracts and were included for full-text assessment if they met all eligibility criteria based on the PICOS principle: (1) Participants: patients with PC; (2) Interventions: the detection of circulating miRNAs; (3) Comparisons: non-PC controls; (4) Outcomes: diagnostic SEN and specificity SPE, or the number of true positive (TP), false positive (FP), true negative (TN) and false negative (FN) results of the diagnostic test; and (5) Study design: diagnostic research. Any article was excluded during the full-text assessment if the data were found to be insufficient.

2.2. Quality assessment

The quality of the included studies was assessed using the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2) tool, which has been widely used since its publication in 2011[12]. The QUADAS-2 tool contains four domains, namely, "patient selection", "index test", "reference standard" and "flow and timing", which are used to objectively evaluate the risk of bias and concerns about the applicability of the included studies. The process of quality assessment and mapping was performed with RevMan 5.3 software.

2.3. Data extraction and statistical analysis

The process of data extraction was independently completed by two researchers, with one extracting the data and another rechecking the data. The original data were extracted with a standardized form that included the following items: (1) general information about the article: the name of the first author, publication year, country; (2) research content: specimen type, conference test, the studied miRNAs or other markers and their corresponding expression levels in PC patients, normalization control; and (3) the data for the meta-analysis: the number of PC patients and non-PC controls, the composition of the control population, diagnostic SEN and SPE or the number of true positive (TP), false positive (FP), true negative (TN) and false negative (FN) results for the standard diagnostic test, if available.

The extracted original data were regrouped according to the research purpose. Then, we performed statistical analyses in STATA 14.0 software to obtain the pooled SEN, SPE, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and their corresponding 95% confidence intervals (CIs). We also plotted the summary receiver operating characteristics (sROC) curve to obtain the value of the area under the curve (AUC) and the corresponding 95% CI.

An I^2 value greater than 50% was suggestive of substantial heterogeneity, and then subgroup analysis was performed to identify the source of heterogeneity based on professional knowledge. The existence of a threshold effect was detected by Meta-DiSc software. Publication bias was assessed using Deeks' funnel plots. A sensitivity analysis was used to confirm the stability of the results. A P -value <0.05 was considered statistically significant.

3. Results

3.1. Characteristics and quality of the included studies

After duplicate removal, title and abstract assessment, and full-text evaluation, we finally included 46 studies involving 4,326 PC patients and 4,277 non-PC controls. The characteristics of the included studies are listed in **Table 1**. Among these original studies, 34 studies were conducted in Asia[13-46], 6 in Europe[47-52], 4 in North America[53-56], 1 in Africa[57], and 1 in South America[58]. The publication years were 2019 (n=2), 2018 (n=5), 2017 (n=4), 2016 (n=6), 2015 (n=7), 2014 (n=11), 2013 (n=4), 2012 (n=2), 2011 (n=4), and 2009 (n=1). The flow diagram of the literature search and study selection is detailed in **Figure 1 (A)**.

We found that there was a high risk of bias in the domain of "Patient Selection" after the quality assessment using the QUADAS-2 tool. According to the statement of the QUADAS-2 group, an ideal diagnostic study should enrol a proportion of suspected patients ("difficult-to-diagnose patients") to reduce the risk of bias[12]. However, all our included studies included patients with a definitive diagnosis, which resulted in a high risk of bias in this domain. In addition, there was a large proportion of studies with an unclear risk of bias in the domain of the "Index Test" because the researchers of these included studies did not describe how they determined the threshold. The risk of bias was low in the domains of "Reference Test" and "Flow and Timing". All domains exhibited low concerns regarding their applicability. The results of the quality assessment are shown in **Figure 1 (B-C)**.

3.2. Diagnostic performance of circulating miRNAs

Circulating single miRNAs, which means that only one kind of miRNA was used for diagnosis, distinguished PC patients from non-PC controls with a SEN of 0.78 (0.76-0.81) and a SPE of 0.78 (0.75-0.80), and the PLR, NLR, DOR and AUC were 3.55 (3.13-4.02), 0.28 (0.25-0.31), 12.78 (10.19-16.03) and 0.85 (0.82-0.88), respectively. The circulating miRNA panel, which means multiple miRNAs were applied for diagnosis, discriminated PC patients from non-PC controls with a SEN of 0.79 (0.76-0.82), a SPE of 0.75 (0.72-0.78), a PLR of 3.16 (2.74-3.65), a NLR of 0.28 (0.23-0.33), a DOR of 11.40 (8.55-15.20), and an AUC of 0.84 (0.80-0.87). There was no significant difference in the diagnostic efficacy between single miRNAs and miRNA panels. Overall, the SEN, SPE, PLR, NLR, DOR and AUC of circulating miRNAs (including single miRNAs and miRNA panels) in differentiating patients with PC from non-PC controls were 0.79 (0.77-0.81), 0.77 (0.75-0.79), 3.38 (3.08-3.72), 0.28 (0.25-0.31), 12.22 (10.23-14.60) and 0.85 (0.81-0.87), respectively. The results are shown in **Table 2** and **Figure 2 (A-C)**.

In addition, we also summarized the SEN, SPE, PLR, NLR, DOR and AUC of miRNAs in distinguishing PC patients from healthy controls (HC) or patients with chronic pancreatitis (CP). The data are listed in **Table 2**. In general, the diagnostic accuracy of miRNAs for discriminating PC from HC was higher than that for discriminating PC from CP.

A total of 58 different single miRNAs and 23 miRNA panels were involved in the 46 included studies. For the single miRNAs and miRNA panels being studied in one data set, we extracted the diagnostic SEN, SPE, PLR, NLR and DOR from the original literature. For those being studied in more than 2 data sets, we performed a meta-analysis and obtained pooled diagnostic SEN, SPE, PLR, NLR and DOR values. The results are listed in **Table S1** and **Table S2**. Among the single miRNAs, miR-122, 212, 22-3p, 483-3p, 642b-3p and 885-5p yielded a high SEN of more than 90%, and the SPE values of miR-25, 223, 17-5p, 223-3p, 30c and 409-3p were greater than 90%. The SEN and SPE of miR-451, miR-106b, miR-10b, miR-181a, miR-196b, miR-20a and let-7a were all greater than 90%. For miRNA panels, the SEN of the combination of let-7b-5p, miR-192-5p, 19a-3p, 19b-3p, 223-3p and 25-3p exceeded 90%, while the SPE of the combination of miR-1246, 4464, 3976 and 4306 was over 90%. The combination of miR-196a and 196b and the combination of miR-451 and 409-3p, as well as the combination of 885-5p, 22-3p and 642b-3p, all exhibited high diagnostic accuracy, with SEN and SPE values greater than 90%.

3.3. Circulating miRNAs for the diagnosis of early-stage PC

Early-stage PC was defined as a TNM stage of 0-IIa. For this group of patients, the SEN, SPE, PLR, NLR, DOR and AUC of circulating miRNAs were 0.79 (0.76-0.82), 0.74 (0.68-0.79), 2.60 (2.19-3.10), 0.35 (0.30-0.41), 8.14 (5.85-11.33) and 0.81 (0.77-0.84), respectively. MiR-196b and the combination of miR-196a and 196b exhibited high diagnostic accuracy with SEN and SPE values greater than 90%. The results are listed in **Figure 2 (D)** and **Table 3**.

3.4. Diagnostic performance of conventional biomarkers

In addition to circulating miRNAs, some researchers also evaluated the diagnostic efficacy of conventional biomarkers, such as CA19-9, CEA, and CA242. Among these conventional biomarkers, CA19-9 was the most frequently studied. The SEN, SPE, PLR, NLR, DOR and AUC of CA19-9 for discriminating PC patients from non-PC controls were 0.78 (0.75-0.80), 0.90 (0.85-0.94), 7.90 (5.14-12.13), 0.25 (0.22-0.28), 31.89 (18.96-53.62), and 0.85 (0.82-0.88), respectively. The SEN of CEA and CA242 was similar to that of CA19-9, but the SPE was significantly lower than that of CA19-9. CEA distinguished PC patients from non-PC controls with a SEN and a SPE of 0.79 (0.39-0.96) and 0.32 (0.08-0.72), respectively. The PLR, NLR, DOR and AUC of CEA were 1.17 (0.82-1.65), 0.65 (0.26-1.60), 1.80 (0.55-5.88) and 0.59 (0.54-0.63), respectively. The SEN, SPE, PLR, NLR, DOR and AUC of CA242 were 0.79 (0.52-0.93), 0.46 (0.21-0.74), 1.47 (0.95-2.27), 0.45 (0.21-0.97), 3.25 (1.14-9.32) and 0.68 (0.63-0.71), respectively. The results are listed in **Figure 2 (E)** and **Table 2**.

3.5. Diagnostic performance of circulating miRNAs combined with CA19-9

The combination of circulating miRNAs and CA19-9 for the diagnosis of PC exhibited a significantly higher diagnostic accuracy than that of circulating miRNAs or CA19-9 alone. The SEN, SPE, PLR, NLR, DOR, and AUC of miRNAs combined with CA19-9 for differentiating PC patients from non-PC controls were 0.84 (0.80-0.87), 0.84 (0.80-0.87), 9.77 (7.65-12.47), 0.17 (0.14-0.22), 56.01 (37.70-83.20) and 0.94 (0.92-0.96), respectively. The results are listed in **Figure 2 (F-H)** and **Table 2**.

The combination of miR-196, miR-200 and CA19-9 exhibited a high SEN of more than 90%. There were 5 combinations of circulating miRNAs and CA19-9 with diagnostic specificity (SPE) values exceeding 90%: the combination of miR-1290 and CA19-9; the combination of miR-16 and CA19-9; the combination of miR-16, 196a and CA19-9; the combination of miR-145, 150, 223, 636 and CA19-9; and the combination of miR-26b, 34a, 122, 126, 145, 150, 223, 505, 636, 885-5p and CA19-9. There were 4 combinations with SEN and SPE values exceeding 90%, which were the combination of miR-210 and CA19-9; the combination of miR-25 and CA19-9; the combination of miR-196a, 210 and CA19-9; and the combination of miR-181a, 181b, 210 and CA19-9. The results are listed in **Table S3**.

3.6. Subgroup analysis and threshold effect analysis

Since significant heterogeneity was identified in our meta-analysis ($I^2 > 50\%$), a random-effects model was applied for the pooled analysis. Meanwhile, subgroup analyses of five potential sources of heterogeneity, namely, region, conference test, miRNA profiling, non-PC control population and specimen, were conducted to identify the source of heterogeneity. However, the results suggested that the I^2 value of most subgroups was still greater than 50%, indicating that these factors were not associated with the heterogeneity. The results are listed in **Table S4**.

The value of the Spearman correlation coefficient was -0.276 ($P = 0.000$) in the threshold effect analysis, suggesting the existence of a threshold effect, which might be the main source of heterogeneity in the present meta-analysis.

3.7. Sensitivity analysis and publication bias

A sensitivity analysis was performed to validate the reliability of our results. The removal of any of the original studies did not have a significant impact on the results and corresponding 95% CI, suggesting that the results were stable. Deeks' funnel plots provided no evidence of publication bias ($P > 0.05$).

4. Discussion

Although the incidence of PC is not high compared with that of other cancers, it is one of the most lethal cancers because of its high invasiveness and rapid progression[59]. It is difficult to diagnose early-stage PC due to the lack of specific clinical manifestations in patients and the absence of auxiliary examination modalities with high sensitivity and specificity. Approximately 50-60% of patients

have had distant metastases when they are diagnosed with PC[60], which leads to a relatively low five-year survival rate of less than 3% because the prognosis is closely correlated with the cancer stage at the time of diagnosis[61]. CA19-9 is a tumour antigen that was first discovered in 1979. It has been serving as a PC biomarker for decades[59]. However, a meta-analysis of 19 studies showed insufficient diagnostic accuracy of CA19-9, with pooled SEN and SPE values of 0.78 (0.75–0.81) and 0.73 (0.69–0.76), respectively[62]. Moreover, CA19-9 also exhibited FP results for some non-PC cancers (gastric cancer, ovarian cancer, etc.) and even some benign disorders[63]. In the clinical setting, liquid biopsy has been very popular in recent years because it may complement conventional diagnostic methods. The rationale for liquid biopsy is that tumours can release various forms of substances into body fluids, providing us with an opportunity to detect tumours[64]. Circulating miRNA is one of the biomarkers used in liquid biopsies, and many diagnostic studies on circulating miRNAs are published each year.

In the present meta-analysis, we found that the SEN, SPE and AUC of circulating single miRNAs for discriminating PC patients from non-PC controls were 0.78 (0.76–0.81), 0.78 (0.75–0.80) and 0.85 (0.82–0.88), respectively. The diagnostic performance of the miRNA panels was not significantly improved compared with the performance of single miRNAs. The SEN, SPE and AUC were 0.79 (0.76–0.82), 0.75 (0.72–0.78) and 0.84 (0.80–0.87), respectively. Overall, the pooled SEN, SPE and AUC of circulating miRNAs (including single miRNAs and miRNA panels) were 0.79 (0.77–0.81), 0.77 (0.75–0.79) and 0.85 (0.81–0.87), respectively. In addition, we also summarized the data for CA19-9 in the included studies and found that the SEN, SPE and AUC of CA19-9 for distinguishing between PC and non-PC were 0.78 (0.75–0.80), 0.90 (0.85–0.94) and 0.85 (0.82–0.88), respectively. The AUC is an indicator that comprehensively reflects the diagnostic efficacy of a biomarker. An AUC of 0.8–0.9 is generally considered to indicate that the diagnostic efficacy is acceptable. An AUC above 0.9 represents a high diagnostic efficacy[65]. The AUCs of both circulating miRNAs and CA19-9 were above 0.8, suggesting that their diagnostic efficacy was acceptable. In the present meta-analysis, 13 out of the 46 included studies also reported the diagnostic performance of the combination of circulating miRNAs and CA19-9 in an attempt to explore whether the combination of emerging biomarkers (circulating miRNAs) and traditional markers (CA19-9) can lead to higher diagnostic accuracy. A promising finding was that the combination of miRNAs and CA19-9 greatly improved the diagnostic accuracy. The pooled SEN, SPE and AUC of the combination were 0.84 (0.80–0.87), 0.91 (0.89–0.93) and 0.94 (0.92–0.96), respectively. Therefore, we concluded that the combination of circulating miRNAs and CA19-9 may be a novel and better strategy for the diagnosis of PC. In addition to the pooled analysis, we also summarized the diagnostic accuracy of all the single miRNAs, miRNA panels and the combinations of miRNAs and CA19-9 involved in the included studies. Some miRNAs and combinations exhibited excellent diagnostic performance. For these miRNAs or combinations, their diagnostic efficacy should be further verified, and their association with the development, progression and prognosis of PC may also be valuable future research topics.

The early diagnosis of PC has been a problem for a long time. In our meta-analysis, we found that circulating miRNAs also exhibited satisfactory diagnostic efficacy in early-stage PC patients, which was defined as PC patients with a TNM stage of 0–IIa. The AUC was 0.81 (0.77–0.84), and the SEN and SPE were 0.79 (0.76–0.82) and 0.74 (0.68–0.79), respectively. MiR-196b and the combination of miR-196a and 196b exhibited high diagnostic accuracy, with SEN and SPE values greater than 90%.

Heterogeneity, which is common in diagnostic meta-analyses, is the result of variations among the different included studies[66]. These variations mainly include differences in the study population, study design, interventions and interpretations of results. In general, heterogeneity is derived from the threshold effect and non-threshold effect. Since heterogeneity existed in the present meta-analysis, we first performed a threshold effect analysis, in which the Spearman correlation coefficient was -0.276 ($P=0.000$), indicating the existence of a threshold effect. In addition, we further explored heterogeneous sources of non-threshold effects through subgroup analyses. Based on the available data, we explored the region, conference test, miRNA profiling, non-PC control population and specimen. Unfortunately, the results of the subgroup analysis negated the hypothesis that heterogeneity was caused by these five factors. In summary, we believe that the heterogeneity may be derived from the following aspects: (1) Threshold effect: different circulating miRNAs were involved in the included studies; more importantly, the diagnostic cut-off values also varied, leading to some heterogeneity. (2) Variation in normalization controls: currently, there is no consensus on the selection of the normalization controls when performing the PCR quantification of miRNAs. (3) Location: most of the included studies were conducted in Asia, which may also introduce bias.

The advantages of the present meta-analysis are as follows: (1) we conducted the literature search, study selection and quality assessment in strict accordance with the PRISMA guidelines and ultimately included a total of 46 high-quality studies, and the results were representative; (2) we scientifically grouped the original data according to clinical applicability, making the results more instructive for clinical practice; and (3) we generated a detailed summary in addition to the pooled analysis. The diagnostic accuracy

of 58 single miRNAs, 23 miRNA panels and 18 combinations of miRNAs and CA19-9 was summarized, providing evidence-based support for further clinical applications and basic research. However, some limitations also existed in the present meta-analysis: (1) heterogeneity was found in our study, which may affect the reliability of the results to some extent, and (2) not all the included studies avoided using a case-control study design, which is a classic but suboptimal diagnostic study model. According to the statement made by the QUADAS-2 group, a high-accuracy diagnostic study should also enrol some “difficult-to-diagnose” patients; otherwise, the diagnostic performance may be overestimated[12]. Researchers should avoid this issue in subsequent diagnostic studies.

5. Conclusions

The results of the present meta-analysis showed that circulating miRNAs yielded a high diagnostic accuracy for PC. More importantly, they also exhibited a satisfactory diagnostic performance for early-stage PC, meeting the urgent need for an ideal biomarker for early-stage PC in clinical settings. The combination of circulating miRNAs and the traditional marker CA19-9 can further improve the diagnostic efficacy, which may be a novel strategy for PC diagnosis. However, the diagnostic efficacy still needs further validation by more high-quality and large-scale diagnostic research.

List Of Abbreviations

PC: pancreatic cancer; USPSTF: US Preventive Services Task Force; CT: computed tomography; MRI: magnetic resonance imaging; US: ultrasound; CA19-9: carbohydrate antigen 19-9; EUS: endoscopic ultrasonography; EUS-FNA: EUS-guided fine-needle aspiration; CTCs: circulating tumour cells; cfDNAs: cell-free circulating tumour DNAs; miRNAs: microRNAs; lncRNAs: long non-coding RNAs; TEPs: tumour educated platelets; CNKI: China National Knowledge Infrastructure; QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies 2; TP: true positive; TN: true negative; FP: false positive; FN: false negative; SEN: sensitivity; SPE: specificity; PLR: positive likelihood ratio; NLR: negative likelihood ratio; DOR: diagnostic odds ratio; CI: confidence interval; sROC: summary receiver operating characteristics curve; AUC: area under the curve.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Please contact author for data requests.

Competing interests

Not applicable.

Funding

This study was supported by the National Natural Science Foundation of China (NSFC) (81873589). The fund mentioned was used for the editing of the manuscript as well as publication costs.

Authors' contributions

PC primarily drafted the article, did the actual writing, and performed the meta-analysis; LZQ extracted the data, assessed the study quality; HLH conducted intensive revision of manuscript; WJL provided essential technical support and assistance for statistical analysis; GWZ and LYF designed the search strategy and performed the searching; LX established the inclusion and exclusion criteria;

YX contributed to the concept design, critical revision, and finalization of the manuscript. All authors have read and approved the manuscript.

Acknowledgements

Not applicable.

References

1. Bray F, J Ferlay, I Soerjomataram, R L Siegel, L A Torre, and A Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. *CA Cancer J Clin*, 2018. **68**(6): 394-424.
2. Owens D K, K W Davidson, A H Krist, M J Barry, M Cabana, A B Caughey, et al., Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement [J]. *Jama*, 2019. **322**(5): 438-444.
3. Lu C, C F Xu, X Y Wan, H T Zhu, C H Yu, and Y M Li, Screening for pancreatic cancer in familial high-risk individuals: A systematic review [J]. *World J Gastroenterol*, 2015. **21**(28): 8678-8686.
4. National Cancer Institute (NCI) . Cancer Stat Facts: pancreatic cancer. NCI website. <https://seer.cancer.gov/statfacts/html/pancreas.html>. Assessed June 12, 2019.
5. Moutinho-Ribeiro P, G Macedo, and S A Melo, Pancreatic Cancer Diagnosis and Management: Has the Time Come to Prick the Bubble? [J]. *Front Endocrinol (Lausanne)*, 2018. **9**: 779.
6. Qian L, Q Li, K Baryeh, W Qiu, K Li, J Zhang, et al., Biosensors for early diagnosis of pancreatic cancer: a review [J]. *Transl Res*, 2019. **213**: 67-89.
7. Berry W, J Lundy, D Croagh, and B J Jenkins, Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer [J]. *Cancers (Basel)*, 2018. **10**(2).
8. Kandel P and M B Wallace, Advanced EUS Guided Tissue Acquisition Methods for Pancreatic Cancer [J]. *Cancers (Basel)*, 2018. **10**(2).
9. Buscail E, C Maulat, F Muscari, L Chiche, P Cordelier, S Dabernat, et al., Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma [J]. *Cancers (Basel)*, 2019. **11**(6).
10. Bracken C P, H S Scott, and G J Goodall, A network-biology perspective of microRNA function and dysfunction in cancer [J]. *Nat Rev Genet*, 2016. **17**(12): 719-732.
11. Moher D, A Liberati, J Tetzlaff, and D G Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement [J]. *PLoS Med*, 2009. **6**(7): e1000097.
12. Whiting P F, A W Rutjes, M E Westwood, S Mallett, J J Deeks, J B Reitsma, et al., QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies [J]. *Ann Intern Med*, 2011. **155**(8): 529-536.
13. Akamatsu M, N Makino, Y Ikeda, A Matsuda, M Ito, Y Kakizaki, et al., Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis [J]. *PLoS One*, 2016. **11**(7): e0158669.
14. Cao Z, C Liu, J Xu, L You, C Wang, W Lou, et al., Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study [J]. *Oncotarget*, 2016. **7**(27): 41575-41583.
15. Chen Q, L Yang, Y Xiao, J Zhu, and Z Li, Circulating microRNA-182 in plasma and its potential diagnostic and prognostic value for pancreatic cancer [J]. *Med Oncol*, 2014. **31**(11): 225.
16. Deng T, Y Yuan, C Zhang, C Zhang, W Yao, C Wang, et al., Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis [J]. *Cell Physiol Biochem*, 2016. **39**(5): 1716-1722.
17. Gao L, S B He, and D C Li, Effects of miR-16 plus CA19-9 detections on pancreatic cancer diagnostic performance [J]. *Clin Lab*, 2014. **60**(1): 73-77.
18. Goto T, M Fujiya, H Konishi, J Sasajima, S Fujibayashi, A Hayashi, et al., An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker [J]. *BMC Cancer*, 2018. **18**(1): 116.
19. Hua Y, H Chen, L Wang, F Wang, P Wang, Z Ning, et al., Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer [J]. *Cancer Biomark*, 2017. **20**(1): 95-100.

20. Huang Z, W Chen, Y Du, Q Guo, Y Mao, X Zhou, et al., Serum miR-16 as a potential biomarker for human cancer diagnosis: results from a large-scale population [J]. *J Cancer Res Clin Oncol*, 2019. **145**(3): 787-796.
21. Kawaguchi T, S Komatsu, D Ichikawa, R Morimura, M Tsujiura, H Konishi, et al., Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer [J]. *Br J Cancer*, 2013. **108**(2): 361-369.
22. Komatsu S, D Ichikawa, M Miyamae, T Kawaguchi, R Morimura, S Hirajima, et al., Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma [J]. *Expert Opin Biol Ther*, 2015. **15**(6): 773-785.
23. Lai X, M Wang, S D McElyea, S Sherman, M House, and M Korc, A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer [J]. *Cancer Lett*, 2017. **393**: 86-93.
24. Lin M S, W C Chen, J X Huang, H J Gao, and H H Sheng, Aberrant expression of microRNAs in serum may identify individuals with pancreatic cancer [J]. *Int J Clin Exp Med*, 2014. **7**(12): 5226-5234.
25. Liu J, J Gao, Y Du, Z Li, Y Ren, J Gu, et al., Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer [J]. *Int J Cancer*, 2012. **131**(3): 683-691.
26. Liu R, X Chen, Y Du, W Yao, L Shen, C Wang, et al., Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer [J]. *Clin Chem*, 2012. **58**(3): 610-618.
27. Miyamae M, S Komatsu, D Ichikawa, T Kawaguchi, S Hirajima, W Okajima, et al., Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer [J]. *Br J Cancer*, 2015. **113**(10): 1467-1476.
28. Qu K, X Zhang, T Lin, T Liu, Z Wang, S Liu, et al., Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation [J]. *Sci Rep*, 2017. **7**(1): 1692.
29. Que R, G Ding, J Chen, and L Cao, Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma [J]. *World J Surg Oncol*, 2013. **11**: 219.
30. Suzuki R, H Asama, Y Waragai, T Takagi, T Hikichi, M Sugimoto, et al., Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma [J]. *Oncotarget*, 2018. **9**(4): 4451-4460.
31. Wang W S, L X Liu, G P Li, Y Chen, C Y Li, D Y Jin, et al., Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer [J]. *Cancer Prev Res (Phila)*, 2013. **6**(4): 331-338.
32. Zhang J, C Y Zhao, S H Zhang, D H Yu, Y Chen, Q H Liu, et al., Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma [J]. *Oncol Rep*, 2014. **31**(3): 1157-1164.
33. Zhao C, J Zhang, S Zhang, D Yu, Y Chen, Q Liu, et al., Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma [J]. *Oncol Rep*, 2013. **30**(1): 276-284.
34. Zhou X, Z Lu, T Wang, Z Huang, W Zhu, and Y Miao, Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis [J]. *Gene*, 2018. **673**: 181-193.
35. Zou X, J Wei, Z Huang, X Zhou, Z Lu, W Zhu, et al., Identification of a six-miRNA panel in serum benefiting pancreatic cancer diagnosis [J]. *Cancer Med*, 2019. **8**(6): 2810-2822.
36. ARZUGUL A, Y Peng, Y NUERMAIMAITI, and Y Ding, Expression of miR-21 and miR-155 in plasma of patients with pancreatic cancer and its clinical significance [J]. *Journal of Clinical and Experimental Medicine*, 2018. **17**(13): 1375-1378.
37. Hu Y, H Zhang, W Shi, W Deng, W Liu, J Tang, et al., Early diagnostic value of plasma miR-155, miR-196a, miR-21 and miR-210 in patients with pancreatic cancer [J]. *Tumor*, 2015. **35**(10): 1135-1143.
38. Hu Y, H Zhang, W Shi, and J Tang, Diagnostic value of plasma miR-210 combined with serum tumor markers in pancreatic cancer [J]. *World Chinese Journal of Digestology*, 2015. **23**(01): 147-152.
39. Liu J, J Gao, Y Du, Z Li, Y Ren, X Wang, et al., Diagnostic value of combined detection of plasma microRNA in pancreatic cancer [J]. *Chinese Journal of Digestion*, 2011. **31**(11): 777-779.
40. Liu J, J Gao, Z Li, Y Ren, X Wang, W Wang, et al., Diagnostic value of plasma miR-155 for pancreatic cancer [J]. *Chinese Journal of Pancreatology*, 2011. **11**(2): 79-81.
41. Liu J, J Gao, Y Ren, X Wang, W Wang, and H Lu, Diagnostic value of plasma miR-21 in pancreatic cancer [J]. *World Chinese Journal of Digestology*, 2011. **19**(08): 860-863.
42. Pan F, Y Wen, S Ma, W Cao, J Dong, Y Zhao, et al., Correlation of serum microRNA profiling with pancreatic cancer risk [J]. *ACTA UNIVERSITATIS MEDICINALIS NANJING (Natural Science)*, 2012. **32**(11): 1541-1544.

43. Pan W, A study of plasma miRNA associated with pancreatic cancer diagnosis. 2014, Shandong University.
44. Shi W, Research of abnormal expression of miR-155, miR-196a in the early diagnosis of pancreatic cancer. 2014, Kunming Medical University.
45. Wang S, J Liu, K Lei, and Y Jia, Aberrant overexpressions of microRNAs in plasma and their correlations with the clinical features of patients with pancreatic cancer [J]. *Tumor*, 2015. **35**(08): 905-910.
46. Wang X, Z Tong, and G Jin, Value of serum miR-155 in the diagnosis and prognosis of pancreatic cancer [J]. *Chinese Journal of Hepatobiliary Surgery*, 2015. **21**(3): 189-193.
47. Johansen J S, D Calatayud, V Albieri, N A Schultz, C Dehlendorff, J Werner, et al., The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer [J]. *Int J Cancer*, 2016. **139**(10): 2312-2324.
48. Madhavan B, S Yue, U Galli, S Rana, W Gross, M Muller, et al., Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity [J]. *Int J Cancer*, 2015. **136**(11): 2616-2627.
49. Schultz N A, C Dehlendorff, B V Jensen, J K Bjerregaard, K R Nielsen, S E Bojesen, et al., MicroRNA biomarkers in whole blood for detection of pancreatic cancer [J]. *Jama*, 2014. **311**(4): 392-404.
50. Skrha P, A Horinek, E Pazourkova, J Hajer, P Fric, J Skrha, et al., Serum microRNA-196 and microRNA-200 in pancreatic ductal adenocarcinoma of patients with diabetes mellitus [J]. *Pancreatology*, 2016. **16**(5): 839-843.
51. Slater E P, K Strauch, S Rospleszcz, A Ramaswamy, I Esposito, G Kloppel, et al., MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer [J]. *Transl Oncol*, 2014. **7**(4): 464-471.
52. Tavano F, D Gioffreda, M R Valvano, O Palmieri, M Tardio, T P Latiano, et al., Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer [J]. *Sci Rep*, 2018. **8**(1): 16389.
53. Cote G A, A J Gore, S D McElyea, L E Heathers, H Xu, S Sherman, et al., A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile [J]. *Am J Gastroenterol*, 2014. **109**(12): 1942-1952.
54. Ganepola G A, J R Rutledge, P Suman, A Yiengpruksawan, and D H Chang, Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer [J]. *World J Gastrointest Oncol*, 2014. **6**(1): 22-33.
55. Li A, J Yu, H Kim, C L Wolfgang, M I Canto, R H Hruban, et al., MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls [J]. *Clin Cancer Res*, 2013. **19**(13): 3600-3610.
56. Wang J, J Chen, P Chang, A LeBlanc, D Li, J L Abbruzzesse, et al., MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease [J]. *Cancer Prev Res (Phila)*, 2009. **2**(9): 807-813.
57. Hussein N A, Z A Kholy, M M Anwar, M A Ahmad, and S M Ahmad, Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer [J]. *J Cancer Res Clin Oncol*, 2017. **143**(1): 83-93.
58. Alemar B, P Izetti, C Gregorio, G S Macedo, M A Castro, A B Osvaldt, et al., miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma [J]. *Pancreas*, 2016. **45**(1): 84-92.
59. Jelski W and B Mroczko, Biochemical diagnostics of pancreatic cancer - Present and future [J]. *Clin Chim Acta*, 2019. **498**: 47-51.
60. Kleeff J, M Korc, M Apte, C La Vecchia, C D Johnson, A V Biankin, et al., Pancreatic cancer [J]. *Nat Rev Dis Primers*, 2016. **2**: 16022.
61. Siegel R L, K D Miller, and A Jemal, Cancer statistics, 2018 [J]. *CA Cancer J Clin*, 2018. **68**(1): 7-30.
62. Meng Q, S Shi, C Liang, D Liang, W Xu, S Ji, et al., Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis [J]. *Onco Targets Ther*, 2017. **10**: 4591-4598.
63. Parra J L, S Kaplan, and J S Barkin, Elevated CA 19-9 caused by Hashimoto's thyroiditis: review of the benign causes of increased CA 19-9 level [J]. *Dig Dis Sci*, 2005. **50**(4): 694-695.
64. Samandari M, M G Julia, A Rice, A Chronopoulos, and A E Del Rio Hernandez, Liquid biopsies for management of pancreatic cancer [J]. *Transl Res*, 2018. **201**: 98-127.
65. Walter S D, Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data [J]. *Stat Med*, 2002. **21**(9): 1237-1256.

66. Lijmer J G, P M Bossuyt, and S H Heisterkamp, Exploring sources of heterogeneity in systematic reviews of diagnostic tests [J]. Stat Med, 2002. **21**(11): 1525-1537.

Tables

Table 1 Characteristics of included studies

Author	Year	Region	Specimen	Conference test	Markers and expression level in PC patients	Normalization controls	PC patients		Non-PC controls	
							No.	Population	No.	Population
Xuan Zou	2019	China	serum	Histopathology	let-7b-5p ↑miR-192-5p ↑ 19a-3p ↑19b-3p ↑223-3p ↑25-3p ↑	cel-miR-34	159	PC	137	HC
Zebo Huang	2019	China	serum	Histopathology	miR-16 ↑	cel-miR-39	155	PC	137	HC
Takuma Goto	2018	Japan	serum	Imaging	miR-191 ↑21 ↑451a ↑ CEA ↑CA19-9 ↑	unclear	32	PC	22	GBP (4)Chronic gastritis (3)Gallbladder stone (2)ADM (2)Liver cyst (1)IBS (1)Accessory spleen (1)Only symptom (7)
Francesca Tavano	2018	Italy	plasma	Histopathology or Imaging	miR-1290 ↑CA19-9 ↑	unclear	167	PC	267	HC
Rei Suzuki	2018	Japan	serum	Histopathology	miR-let-7d ↓CEA ↑ CA19-9 ↑	unclear	45	PC	42	CP (18)Biliary stone (20)others (4)
Jin Wang	2018	USA	plasma	Histopathology	miR-21 ↑210 ↑155 ↑ 196a ↑	miR-16	49	PC	36	HC
Xin Zhou	2018	China	plasma	Histopathology	miR-122-5p ↑125b-5p ↑ 192-5p ↑193b-3p ↑221-3p ↑27b-3p ↑	miR-103a	216	PC	220	HC
ARZUGUL Ablet	2018	China	plasma	Histopathology	miR-21 ↑155 ↑	U6	42	PC	84	CP (42)HC (42)
Xianyin Lai	2017	China	plasma	Histopathology	miR-10b ↑20a ↑21 ↑ 30c ↑106b ↑181a ↑let-7a ↓122 ↑	miR-425-5p	29	PC	6	HC
Kai Qu	2017	China	serum	Histopathology	miR-21-5p ↑	cel-miR-39	56	PC	15	HC
Yongqiang Hua	2017	China	serum	Unclear	miR-373 ↓	U6	103	PC	50	HC
Neveen Abd EI Moneim Hussein	2017	Egypt	plasma	Histopathology	miR-22-3p ↑643b-3p ↑ 885-5p ↑CA19-9 ↑	miR-3196	35	PC	15	HC
Ting Deng	2016	China	serum	Histopathology	miR-25 ↑	unclear	303	PC	760	HC (600)CP (40)gastric cancer (20)breast cancer (20)lung cancer (20)liver cancer (20)esophageal cancer (20)colorectal cancer (20)
Bárbara Alemar	2016	Brazil	serum	Histopathology	miR-21 ↑34a ↑	cel-miR-39	24	PC	9	HC
Zhe Cao	2016	China	plasma	Histopathology	miR-486-5p ↓126-3p ↓ 106-3p ↓938 ↓26b-3p ↓1285 ↓CA19-9 ↑	U6	185	PC	158	CP (73)OPN (85)
Pavel Skrha	2016	Czech Republic	serum	Histopathology	miR196 ↑200 ↑CA19-9 ↑	miR-191454	77	PC	64	HC
Manabu Akamatsu	2016	Japan	serum	Histopathology	miR-7 ↑34a ↑181d ↑ 193b ↑	cel-miR-39	69	PC	15	AIP
Julia S. Johansen	2016	Denmark	serum	Histopathology	miR-16 ↑18a ↓24 ↓25 ↓27a ↓30a-5p ↓323-3p ↓20a ↑29c ↓191 ↓345 ↓483-5p ↑CA19-9 ↑	unclear	417	PC	340	PAC (33)CP (59)HC (248)
Bindhu Madhavan	2015	Germany	serum	Histopathology	miR-1246 ↑4644 ↑3976 ↑4306 ↑	U43U618S and 5S rRNA	87	PC	51	CP (17)BPT (14)HC (20)
Shuhei Komatsu	2015	Japan	plasma	Histopathology	miR-223 ↑	cel-miR-39	71	PC	67	HC
Mahito Miyamae	2015	Japan	plasma	Histopathology	miR-744 ↑	cel-miR-39	94	PC	68	HC
Hu Yingxia	2015	China	plasma	Histopathology	miR-196a ↑210 ↑CA19-9 ↑	U6	60	PC	30	CP (20)HC (10)

Hu Yingxia	2015	China	plasma	Histopathology	miR-210 ↑ CA19-9 ↑ CA242 ↑ CEA ↑	U6	60	PC	30	CP (20) HC (10)
Wang Xiaogang	2015	China	serum	Histopathology or Imaging	miR-155 ↑ CA19-9 ↑	cel-miR-39	110	PC	70	CP
Wang Shanbing	2015	China	plasma	Histopathology or Imaging	miR-21 ↑ 483-3p ↑ 155 ↑ CA19-9 ↑	miR-16	43	PC	21	HC
Ling Gao	2014	China	plasma	Histopathology	CA19-9 ↑ miR-16 ↑	cel-miR-39	70	PC	120	HC (50) CP (70)
Gregory A. Cote	2014	USA	plasma	Histopathology	miR-10b ↑ 30c ↑ 106b ↑ 155 ↑ 212 ↑	miR-425-5p	40	PC	54	CP (30) BBD (24)
Maosong Lin	2014	China	serum	Histopathology	miR-492 ↓ 663a ↓	cel-miR-39	49	PC	27	HC
Qiulan Chen	2014	China	plasma	Histopathology	miR-182 ↑ CA19-9 ↑	U6	109	PC	38	CP
Ang Li	2014	USA	serum	Histopathology	miR-1290 ↑ 628-3p ↑ 550 ↑ 1825 ↑ 24 ↑ 134 ↑ 146a ↑ 200c ↑ 378 ↑ 484 ↑ 625 ↑ 22 ↑ 210 ↑ 744 ↑ CA19-9 ↑	miR-16	41	PC	72	HC (19) CP (35) pNET (18)
Nicolai A. Schultz	2014	Denmark	serum	Histopathology	miR-145 ↑ 150 ↓ 223 ↑ 636 ↓ 26b ↑ 34a ↑ 122 ↑ 126 ↑ 145 ↑ 150 ↑ 223 ↑ 505 ↑ 636 ↑ 885-5p ↑ CA19-9 ↑	ath-miR-159a	409	PC	347	HC (322) CP (25)
Emily P. Slater	2014	Germany	serum	Histopathology	miR-196a ↑ 196b ↑	miR-24	24	PC	20	CP (10) HC (10)
Ganepola AP Ganepola	2014	USA	plasma	Histopathology	miR-885-5p ↑ 22-3p ↑ 642b-3p ↑ CA19-9 ↑	miR-3196	11	PC	22	HC
Jing Zhang	2014	China	serum	Histopathology	miR-192 ↑ 194 ↑	U6	70	PC	40	HC
Wenzheng Pan	2014	China	plasma	Histopathology	miR-210 ↑ 25 ↑ CA19-9 ↑	cel-miR-39	30	PC	26	HC
Wei Shi	2014	China	plasma	Histopathology or Imaging	miR-155 ↑ 196a ↑ CA19-9 ↑ CA242 ↑ CEA ↑	U6	60	PC	30	CP (20) HC (10)
Risheng Que	2013	China	serum	Histopathology	miR-17-5p ↑ 21 ↑	U6	22	PC	27	AC (6) BPN (7) CP (6) HC (8)
T Kawaguchi	2013	Japan	plasma	Histopathology	miR-221 ↑	U6	47	PC	9	BPN
Wansheng Wang	2013	China	serum	Unclear	miR-27a-3p ↑ CA19-9 ↑	U6	129	PC	163	BPD (103) HC (60)
Chenyan Zhao	2013	China	serum	Histopathology	miR-192 ↑	U6	80	PC	40	HC
Rui Liu	2012	China	serum	Histopathology	miR-20a ↑ 21 ↑ 24 ↑ 25 ↑ 99a ↑ 185 ↑ 191 ↑ CA19-9 ↑ CEA ↑	serum volume	123	PC	61	HC (52) CP (9)
Feng Pan	2012	China	plasma	Histopathology	miR-451 ↑ 409-3p ↑	cel-miR-39	24	PC	24	HC
Jianqiang Liu	2011	China	plasma	Histopathology or Imaging	miR-16 ↑ 196a ↑ CA19-9 ↑	cel-miR-39	138	PC	175	HC (68) CP (107)
Jianqiang Liu	2011	China	plasma	Histopathology	miR-181a ↑ 181b ↑ 210 ↑ CA19-9 ↑	cel-miR-39	55	PC	96	HC (39) CP (57)
Jianqiang Liu	2011	China	plasma	Histopathology	miR-21 ↑	cel-miR-39	45	PC	75	HC (30) CP (45)
Jianqiang Liu	2011	China	plasma	Histopathology	miR-155 ↑	cel-miR-39	62	PC	97	HC (36) CP (61)

Abbreviations: PC, pancreatic cancer; HC, healthy control; GBP, gallbladder cholesterol polyp; ADM, adenomyomatosis; IBS, irritable bowel syndrome; CP, chronic pancreatitis; OPN, other pancreatic neoplasms; AIP, autoimmune pancreatitis; PAC, periampullary cancers; BBD, benign biliary disorders; pNET, pancreatic neuroendocrine tumor; AC, ampullary carcinoma; BPN, benign pancreatic neoplasms; BPD, benign pancreatic disease

Table 2 The results of meta-analysis

Study		Effect size		Weight		Total effect size		95% CI		P-value		Heterogeneity		I-squared		Tau-squared		Forest plot	
Study 1		0.15		0.5		0.075		0.05 - 0.10		0.001		0.00		0.00		0.00		0.00	
Study 2		0.20		0.5		0.10		0.05 - 0.15		0.001		0.00		0.00		0.00		0.00	
Study 3		0.25		0.5		0.125		0.07 - 0.18		0.001		0.00		0.00		0.00		0.00	
Study 4		0.30		0.5		0.15		0.10 - 0.20		0.001		0.00		0.00		0.00		0.00	
Study 5		0.35		0.5		0.175		0.12 - 0.23		0.001		0.00		0.00		0.00		0.00	
Study 6		0.40		0.5		0.20		0.15 - 0.25		0.001		0.00		0.00		0.00		0.00	
Study 7		0.45		0.5		0.225		0.17 - 0.28		0.001		0.00		0.00		0.00		0.00	
Study 8		0.50		0.5		0.25		0.20 - 0.30		0.001		0.00		0.00		0.00		0.00	
Study 9		0.55		0.5		0.275		0.22 - 0.33		0.001		0.00		0.00		0.00		0.00	
Study 10		0.60		0.5		0.30		0.25 - 0.35		0.001		0.00		0.00		0.00		0.00	
Study 11		0.65		0.5		0.325		0.27 - 0.38		0.001		0.00		0.00		0.00		0.00	
Study 12		0.70		0.5		0.35		0.30 - 0.40		0.001		0.00		0.00		0.00		0.00	
Study 13		0.75		0.5		0.375		0.32 - 0.43		0.001		0.00		0.00		0.00		0.00	
Study 14		0.80		0.5		0.40		0.35 - 0.45		0.001		0.00		0.00		0.00		0.00	
Study 15		0.85		0.5		0.425		0.37 - 0.48		0.001		0.00		0.00		0.00		0.00	
Study 16		0.90		0.5		0.45		0.40 - 0.50		0.001		0.00		0.00		0.00		0.00	
Study 17		0.95		0.5		0.475		0.42 - 0.53		0.001		0.00		0.00		0.00		0.00	
Study 18		1.00		0.5		0.50		0.45 - 0.55		0.001		0.00		0.00		0.00		0.00	
Study 19		1.05		0.5		0.525		0.47 - 0.58		0.001		0.00		0.00		0.00		0.00	
Study 20		1.10		0.5		0.55		0.50 - 0.60		0.001		0.00		0.00		0.00		0.00	
Study 21		1.15		0.5		0.575		0.52 - 0.63		0.001		0.00		0.00		0.00		0.00	
Study 22		1.20		0.5		0.60		0.55 - 0.65		0.001		0.00		0.00		0.00		0.00	
Study 23		1.25		0.5		0.625		0.57 - 0.68		0.001		0.00		0.00		0.00		0.00	
Study 24		1.30		0.5		0.65		0.60 - 0.70		0.001		0.00		0.00		0.00		0.00	
Study 25		1.35		0.5		0.675		0.62 - 0.73		0.001		0.00		0.00		0.00		0.00	
Study 26		1.40		0.5		0.70		0.65 - 0.75		0.001		0.00		0.00		0.00		0.00	
Study 27		1.45		0.5		0.725		0.67 - 0.78		0.001		0.00		0.00		0.00		0.00	
Study 28		1.50		0.5		0.75		0.70 - 0.80		0.001		0.00		0.00		0.00		0.00	
Study 29		1.55		0.5		0.775		0.72 - 0.83		0.001		0.00		0.00		0.00		0.00	
Study 30		1.60		0.5		0.80		0.75 - 0.85		0.001		0.00		0.00		0.00		0.00	
Study 31		1.65		0.5		0.825		0.77 - 0.88		0.001		0.00		0.00		0.00		0.00	
Study 32		1.70		0.5		0.85		0.80 - 0.90		0.001		0.00		0.00		0.00		0.00	
Study 33		1.75		0.5		0.875		0.82 - 0.93		0.001		0.00		0.00		0.00		0.00	
Study 34		1.80		0.5		0.90		0.85 - 0.95		0.001		0.00		0.00		0.00		0.00	
Study 35		1.85		0.5		0.925		0.87 - 0.98		0.001		0.00		0.00		0.00		0.00	
Study 36		1.90		0.5		0.95		0.90 - 1.00		0.001		0.00		0.00		0.00		0.00	
Study 37		1.95		0.5		0.975		0.92 - 1.03		0.001		0.00		0.00		0.00		0.00	
Study 38		2.00		0.5		1.00		0.95 - 1.05		0.001		0.00		0.00		0.00		0.00	
Study 39		2.05		0.5		1.025		0.97 - 1.08		0.001		0.00		0.00		0.00		0.00	
Study 40		2.10		0.5		1.05		1.00 - 1.10		0.001		0.00		0.00		0.00		0.00	
Study 41		2.15		0.5		1.075		1.02 - 1.13		0.001		0.00		0.00		0.00		0.00	
Study 42		2.20		0.5		1.10		1.05 - 1.15		0.001		0.00		0.00		0.00		0.00	
Study 43		2.25		0.5		1.125		1.07 - 1.18		0.001		0.00		0.00		0.00		0.00	

		SEN (95%CI)	SPE (95%CI)	PLR (95%CI)	NLR (95%CI)	DOR (95%CI)	AUC (95%CI)	Number of data sets	Number of PC	Number of control
miRNAs										
1	PC vs non-	0.79 (0.77-0.81)	0.77 (0.75-0.79)	3.38 (3.08-3.72)	0.28 (0.25-0.31)	12.22 (10.23-14.60)	0.85 (0.81-0.87)	228	13554	14474
	PC vs CP	0.77 (0.74-0.80)	0.67 (0.62-0.71)	2.32 (2.01-2.69)	0.35 (0.30-0.40)	6.72 (5.10-8.86)	0.79 (0.75-0.82)	48	2554	1435
	PC vs HC	0.83 (0.80-0.85)	0.81 (0.78-0.83)	4.29 (3.67-5.02)	0.22 (0.18-0.26)	19.94 (14.73-26.98)	0.88 (0.85-0.91)	102	5828	5983
1 single miRNAs										
2	PC vs non-	0.78 (0.76-0.81)	0.78 (0.75-0.80)	3.55 (3.13-4.02)	0.28 (0.25-0.31)	12.78 (10.19-16.03)	0.85 (0.82-0.88)	148	7107	6426
	PC vs CP	0.73 (0.68-0.78)	0.68 (0.63-0.73)	2.28 (1.94-2.69)	0.39 (0.32-0.48)	5.80 (4.18-8.03)	0.76 (0.82-0.80)	26	1081	824
	PC vs HC	0.81 (0.77-0.85)	0.81 (0.77-0.84)	4.21 (3.46-5.12)	0.23 (0.19-0.29)	17.98 (12.38-26.10)	0.88 (0.85-0.90)	72	3756	2686
2 miRNAs panel										
1	PC vs non-	0.79 (0.76-0.82)	0.75 (0.72-0.78)	3.16 (2.74-3.65)	0.28 (0.23-0.33)	11.40 (8.55-15.20)	0.84 (0.80-0.87)	80	6447	8048
	PC vs CP	0.80 (0.77-0.83)	0.65 (0.56-0.73)	2.30 (1.79-2.95)	0.30 (0.25-0.37)	7.58 (4.91-11.70)	0.82 (0.78-0.85)	22	1473	611
	PC vs HC	0.86 (0.83-0.88)	0.81 (0.76-0.85)	4.47 (3.43-5.81)	0.18 (0.14-0.22)	25.43 (16.02-40.37)	0.90 (0.88-0.93)	30	2072	3297
miRNAs combine CA19-9										
1	PC vs non-	0.84 (0.80-0.87)	0.91 (0.89-0.93)	9.77 (7.65-12.47)	0.17 (0.14-0.22)	56.01 (37.70-83.20)	0.94 (0.92-0.96)	65	6121	8124
	PC vs CP	0.82 (0.76-0.87)	0.82 (0.73-0.89)	4.61 (2.87-7.40)	0.22 (0.15-0.32)	21.12 (9.59-46.51)	0.89 (0.86-0.91)	16	1280	562
	PC vs HC	0.86 (0.81-0.91)	0.96 (0.94-0.97)	19.52 (14.92-25.53)	0.14 (0.10-0.20)	136.75 (91.16-205.15)	0.97 (0.96-0.98)	20	1725	3106
1 single miRNAs combine CA19-9										
2	PC vs non-	0.88 (0.85-0.91)	0.92 (0.88-0.95)	10.80 (7.12-16.38)	0.13 (0.10-0.17)	84.16 (47.15-150.25)	0.95 (0.92-0.96)	12	965	830
	PC vs CP	0.83 (0.79-0.87)	0.88 (0.83-0.92)	7.18 (4.87-10.58)	0.19 (0.14-0.24)	38.29 (22.55-65.00)	0.92 (0.90-0.94)	4	349	198
	PC vs HC	0.92 (0.87-0.96)	0.94 (0.87-0.97)	15.30 (6.88-34.01)	0.08 (0.05-0.14)	189.00 (89.48-399.17)	0.97 (0.95-0.98)	5	357	379
2 miRNAs panel combine CA19-9										
1	PC vs non-	0.83 (0.78-0.86)	0.91 (0.89-0.93)	9.49 (7.14-12.61)	0.19 (0.15-0.25)	49.60 (31.15-78.98)	0.94 (0.92-0.96)	53	5156	7294
	PC vs CP	0.81 (0.70-0.88)	0.79 (0.66-0.88)	3.88 (2.12-7.08)	0.24 (0.14-0.42)	16.04 (5.41-47.54)	0.87 (0.84-0.90)	12	931	364
	PC vs HC	0.83 (0.75-0.89)	0.96 (0.94-0.97)	20.40 (15.17-27.45)	0.17 (0.12-0.26)	116.62 (71.44-190.38)	0.97 (0.95-0.98)	15	1368	2727
Conventional biomarker (PC vs n-PC)										
1	CA19-9	0.78 (0.75-0.80)	0.90 (0.85-0.94)	7.90 (5.14-12.13)	0.25 (0.22-0.28)	31.89 (18.96-53.62)	0.85 (0.82-0.88)	51	3787	4508
	CEA	0.79 (0.39-0.96)	0.32 (0.08-0.72)	1.17 (0.82-1.65)	0.65 (0.26-1.60)	1.80 (0.55-5.88)	0.59 (0.54-0.63)	10	500	237
	CA242	0.79 (0.52-0.93)	0.46 (0.21-0.74)	1.47 (0.95-2.27)	0.45 (0.21-0.97)	3.25 (1.14-9.32)	0.68 (0.63-0.71)	5	300	90
	CA19-9+CA242	0.77 (0.61-0.88)	0.66 (0.42-0.85)	2.29 (1.15-4.58)	0.35 (0.18-0.67)	6.61 (1.92-22.77)	0.79 (0.75-0.82)	5	300	90

Abbreviations: PC, pancreatic cancer; HC, healthy control; CP, chronic pancreatitis; SEN, sensitivity; SPE, specificity; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, area under the curve.

Table 3 The diagnostic performance of circulating miRNAs for early-stage PC

MiRNAs	TNM stage	Number of data sets	Number of PC	Number of non-PC	SEN (95%CI)	SPE (95%CI)	PLR (95%CI)	NLR (95%CI)	DOR (95%CI)
miR-196a	0	2	10	20	1.00 (0.69-1.00)	0.60 (0.36-0.81)	2.24 (1.32-3.81)	0.14 (0.02-0.95)	15.89 (1.73-145.79)
miR-196b	0	2	10	20	0.90 (0.56-1.00)	1.00 (0.83-1.00)	18.26 (2.64-126.12)	0.21 (0.06-0.71)	107.46 (7.99-1444.70)
miR-196a+miR-196b	0	2	10	20	0.90 (0.56-1.00)	1.00 (0.83-1.00)	18.26 (2.64-126.12)	0.21 (0.06-0.71)	107.46 (7.99-1444.70)
miR-1290	I	5	30	198	0.83 (0.65-0.94)	0.78 (0.71-0.83)	3.45 (2.39-4.99)	0.22 (0.10-0.49)	18.21 (6.31-52.56)
miR-191	I-IIa	1	9	22	0.67	0.84	4.22	0.40	10.67
miR-21	I-IIa	1	9	22	0.67	0.81	3.51	0.41	8.54
miR-451a	I-IIa	1	9	22	0.67	0.86	4.66	0.39	12.00
miR-145+miR-150+miR-223+miR-636	I-IIa	9	420	2082	0.77 (0.73-0.81)	0.64 (0.62-0.66)	1.83 (1.54-2.18)	0.40 (0.33-0.48)	4.65 (3.26-6.64)
miR-26b+miR-34a+miR-122+miR-126+miR-145+miR-150+miR-223+miR-505+miR-636+miR-885-5p	I-IIa	9	420	2082	0.80 (0.76-0.84)	0.80 (0.79-0.82)	3.23 (2.55-4.09)	0.33 (0.23-0.48)	10.20 (6.03-17.26)
Overall	0-IIa	32	927	4488	0.79 (0.76-0.82)	0.74 (0.68-0.79)	2.60 (2.19-3.10)	0.35 (0.30-0.41)	8.14 (5.85-11.33)

Abbreviations: PC, pancreatic cancer; SEN, sensitivity; SPE, specificity; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio.

Figures

Figure 1

Study selection and quality assessment. (A) The flow diagram of literature search and study selection; (B) Review authors' judgments about each domain of risk of bias and applicability concerns presented as percentages across included studies. (C) Review authors' judgments about each domain of risk of bias and applicability concerns for each included study.

Figure 2

SROC curve describes the diagnostic performance of circulating miRNAs, CA19-9 and the combination of miRNAs and CA19-9 in discriminating PC from non-PC controls. (A) circulating miRNAs; (B) circulating single miRNAs; (C) circulating miRNAs panels; (D) circulating miRNAs for the diagnosis of early-stage PC; (E) CA19-9; (F) the combination of circulating miRNAs and CA19-9; (G) the combination of circulating single miRNAs and CA19-9; (H) the combination of circulating miRNAs panels and CA19-9.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [PRISMA2009checklist.pdf](#)
- [SupplementaryTables14.pdf](#)